TIAA CREF Investment Management’s Larimar Therapeutics LRMR Stock Holding History

TIAA CREF Investment Management’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$145K	Hold	4,410	–	–	﹤0.01%	2922
2018 Q4	$262K	Hold	4,410	–	–	﹤0.01%	2809
2018 Q3	$619K	Buy	4,410 +1,492	+51%	+$181K	﹤0.01%	2628
2018 Q2	$358K	Buy	+2,918	New	+$248K	﹤0.01%	2902
2017 Q4	–	Sell	-4,601	Closed	-$194K	–	3070
2017 Q3	$194K	Hold	4,601	–	–	﹤0.01%	3047
2017 Q2	$194K	Sell	4,601 -9,552	-67%	-$489K	﹤0.01%	3090
2017 Q1	$791K	Buy	14,153 +4,109	+41%	+$204K	﹤0.01%	2627
2016 Q4	$383K	Sell	10,044 -1,749	-15%	-$70.9K	﹤0.01%	2922
2016 Q3	$468	Sell	11,793 -1,935	-14%	-$87.9K	﹤0.01%	2874
2016 Q2	$987K	Buy	13,728 +3,942	+40%	+$312K	﹤0.01%	2513
2016 Q1	$784K	Buy	9,786 +4,613	+89%	+$364K	﹤0.01%	2607
2015 Q4	$390K	Hold	5,173	–	–	﹤0.01%	2960
2015 Q3	$1.98M	Sell	5,173 -183	-3%	-$82.5K	﹤0.01%	2145
2015 Q2	$2.23M	Buy	5,356 +2,271	+74%	+$950K	﹤0.01%	2235
2015 Q1	$1.47M	Buy	3,085 +451	+17%	+$214K	﹤0.01%	2416
2014 Q4	$975K	Buy	2,634 +1,388	+111%	+$358K	﹤0.01%	2668
2014 Q3	$294K	Buy	+1,246	New	+$282K	﹤0.01%	3061

Other funds holding LRMR

AVA

Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

TIAA CREF Investment Management's LRMR Position: Q1 2019 in Review

TIAA CREF Investment Management held its Larimar Therapeutics (LRMR) position steady in Q1 2019 at 4,410 shares worth $145K. The position accounts for ﹤0.01% of the portfolio, ranked #2922.

TIAA CREF Investment Management first reported a position in LRMR in Q3 2014 and has held it in 17 quarters since. The position peaked at $2.23M in Q2 2015. 85 funds tracked by Wall St. Rank hold LRMR as of Q1 2019.

TIAA CREF Investment Management held 4,410 shares of Larimar Therapeutics worth $145K as of Q1 2019.
TIAA CREF Investment Management left its Larimar Therapeutics share count unchanged in Q1 2019.
Larimar Therapeutics made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2922 holding.
TIAA CREF Investment Management first reported a position in Larimar Therapeutics in Q3 2014 and has held it in 17 quarters since.
TIAA CREF Investment Management's Larimar Therapeutics position peaked at $2.23M in Q2 2015.
85 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.